Mapp Biopharmaceutical
Press Inquiries
  • About Us
  • Product Development
  • News
    • In the News
    • Press Releases
  • Publications
  • Job Openings
  • Expanded Access Policy
  • Contact Us

New human trials for novel antibody offer hope for immediate protection against deadly Nipah

Jul 3, 2024

New human trials for novel antibody offer hope for immediate protection against deadly Nipah   3 July 2024; OSLO;...

read more

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

May 15, 2024

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus...

read more

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

Oct 27, 2022

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus...

read more

ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus

Oct 4, 2022

ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus     The...

read more

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

Jan 13, 2021

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA...

read more

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

Jun 11, 2019

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical...

read more

Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses

Jan 11, 2019

Public Release

read more

MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure

Sep 28, 2018

MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO,...

read more

Recent News

New human trials for novel antibody offer hope for immediate protection against deadly Nipah

Jul 3, 2024

New human trials for novel antibody offer hope for immediate protection against deadly Nipah   3 July 2024; OSLO; CALIFORNIA; Twenty-five years after the first human outbreak of Nipah virus, a novel Nipah monoclonal antibody—which could offer people at risk of...

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

May 15, 2024

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic,...

Additional Information

  • New Clinical Study
  • FCOI Policy
  • Purchase Order Terms and Conditions
  • Know Your Rights: Workplace Discrimination is Illegal
  • Institutional Biosafety Committee (NIH)
  •  Affirmative Action Policy Statement for Protected Veterans and Individuals with Disabilities
Jobs Opportunities

© 2017-2024 Mapp Biopharmaceutical. All Rights Reserved.